ADRC News

Dr. Walaszek chatted with host Jan Miyasaki about what new treatments are available, what the annual event will focus on and how ageism impacts society’s views on aging.

Sterling Johnson, PhD, discussed strategies to prevent Alzheimer’s disease and the research being done by the Wisconsin Registry for Alzheimer’s Prevention (WRAP) on Wisconsin Public Radio (WPR).

Lifestyle and chronic health conditions in middle age, along with a person’s education level, show associations with emerging blood markers of neurodegeneration and Alzheimer's disease.

More than 50 students and faculty from the University of Wisconsin–Madison participated and presented at the 2023 Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands.

Nathaniel Chin, MD, joined WPR's Central Time and The Morning Show to discuss the FDA's full approval of Leqembi (lecanemab-Irmb) and dementia care.

Nathaniel Chin, MD, was quoted in an article by CNN highlighting the Phase 3 clinical trial results of donanemab, a monoclonal antibody seeking approval from the U.S. Food and Drug Administration (FDA).

Maria Mora Pinzon, MD, MS, spoke to Telemundo Wisconsin about the approval of the Alzheimer’s disease treatment Leqembi (lecanemab-Irmb).

Maria Mora Pinzon, MD, MS, FACPM, and Beth Fields, PhD, OTR/L, BCG, have been named 2023 Faculty Scholars with the National Institute on Aging (NIA) IMPACT Collaboratory.

The council focuses on emerging issues and supports the development of resources and programs for psychiatric education across the United States.

Cynthia Carlsson, MD, MS, spoke to multiple media outlets after the U.S. Food and Drug Administration’s (FDA) full approval of lecanemab was announced. She emphasized the treatment will only be approved for people who are diagnosed with mild cognitive impairment (MCI) or mild dementia and also meet other limited criteria.